A Randomized, Multi-Centre, Open-Label Study of Neo-adjuvant Taxanes and Capecitabine(TX) versus Taxanes and Anthracycline(TA) for Breast Cancer

The patients with breast cancer are randomly assigned to one of two groups, receiving taxanes and capecitabine(TX) or taxanes and anthracycline(TA) regimen in neoadjuvant setting. The treatment response would be evaluated after the completion of two cycles. In compelte response , partial response, and stable patients, the therapy will be continued to four cycles , but patients with progressive lesions will be excluded(individualized therapy will be considered). After four cycle chemotherapy, surgery will be carried out and pathological response will be assessed. The specific surgery type, breast conserving surgery or modified radical mastectomy, will be dependent on individual patient. 1. TX arm: paclitaxel 175mg/m2, or docetaxel 75 mg/m2, introvenous, once every 3 weeks, combined with Capecitabine 1000mg/m2, oral, twice every day for 14 days,every 3 weeks. 2. TA arm: paclitaxel 175mg/m2, or docetaxel 75 mg/m2, introvenous, once every 3 weeks, combined with epirubicin 75mg/m2, introvenous, once every 3 weeks.